Continuing Education Activity

Meningococcemia is a severe and potentially life-threatening infection of the bloodstream caused by Neisseria meningitidis, which can manifest as meningitis, septicemia, or both. The infection begins with asymptomatic nasopharynx colonization, followed by transmission through respiratory droplets requiring close contact. Infants and adolescents are the most vulnerable due to waning maternal antibodies and high nasopharyngeal colonization rates, respectively. Clinically, meningococcemia presents with fever, hemorrhagic rash, and signs of circulatory collapse, often progressing rapidly to septic shock. 

This course explores this potentially lethal infection, including its underlying etiology and associated complications such as metabolic derangements and hematologic abnormalities. Prompt recognition and aggressive management are crucial to reducing morbidity and mortality. This activity for healthcare professionals is designed to enhance the learner's competence in identifying meningococcemia, performing the recommended evaluation, and implementing an appropriate interprofessional approach when managing this condition.

Objectives:

• Identify the etiology of meningococcemia.
• Assess the signs and symptoms of a patient with meningococcemia.
• Implement the appropriate management approach for meningococcemia.
• Apply interprofessional team strategies to improve care coordination and outcomes in patients with meningococcemia.

Access free multiple choice questions on this topic.

Introduction

One of the most serious and life-threatening infectious diseases during childhood is bacteremia, a consequence of which is septic shock, where inadequate perfusion of tissues occurs due to endotoxemia.[1] Neisseria meningitidis (Meningococcus) is a significant bacterial infection of the bloodstream manifesting as meningitis, septicemia, or, more often, a combination of both. Asymptomatic pharyngeal colonization is the initial step of infection, with humans being the natural reservoirs. Transmission occurs by respiratory droplets and requires close, direct contact.[2] 

The invasive meningococcal disease is most commonly seen in 2 age groups: infants who are vulnerable due to disappearance in the early life of the maternal antibodies and adolescents with a high rate of colonization of the nasopharynx.[3][4] In some children, the predominant feature is cardiovascular collapse leading to septic shock.

Etiology

N. meningitidis is a gram-negative coccus in pairs with adjacent sides flattened. This nonmotile, aerobic, facultatively anaerobic pathogen is classified into 12 serogroups based on its capsular polysaccharide. Serogroups A, B, C, W-135, X, and Y are the most common causes of invasive disease worldwide.[5] Please see StatPearls' companion resource, "Meningococcal Disease (Neisseria Meningitidis Infection)", for further information on the microbiology and etiology of meningococcal disease.

Epidemiology

In the United States, invasive N. meningitidis infections are reported through the National Notifiable Diseases Surveillance System. The incidence of meningococcal disease has steadily declined in the United States since the introduction of routine and booster meningococcal vaccines.[6] 

Internationally, the highest incidence rate of invasive meningococcal disease is seen in a belt across sub-Saharan Africa, termed the meningitis belt, where serogroups A and W-135 predominate.[7] International outbreaks of N. meningitidis infections have occurred in association with the Hajj pilgrimage to Mecca.[8]  Please see StatPearls' companion resource, "Meningococcal Disease (Neisseria Meningitidis Infection)", for further information on the incidence and mortality of meningococcal disease.

Pathophysiology

The primary cause of cardiovascular collapse from sepsis is a peripheral circulatory failure. Cardiac dysfunction due to myocardial failure plays a prominent role in meningococcal disease. Higher endotoxin (LOS) concentrations were associated with shock, renal failure, and respiratory distress. High concentrations of IL-6 and IL-8 are seen in those with meningococcal shock. TNF and IL-1 activate endothelial cells by increasing their permeability and adhesiveness for white cells. The overproduction of nitric oxide lowers arterial pressure due to vasodilation and also impairs cardiac contractility.

Endothelial cell retraction on interaction with bacterial endothelial cells leads to a loss of integrity, causing capillary hemorrhages and the formation of thrombi in purpuric lesions. When a large number of bacteria colonize the blood vessels and lead to the corresponding signaling, this is responsible for the extensive purpuric lesions and severity of shock in Purpura fulminans.[9]

Histopathology

Histology of skin lesions shows endothelial necrosis of capillaries and small veins in the dermis and subcutaneous tissue. Neutrophil infiltration and occlusion of vessels with WBCs, platelets, fibrin thrombi, and hemorrhage are seen. Meningococci are seen within the endothelium and thrombi.

History and Physical

Clinical Features of Meningococcemia

The disease spectrum caused by N. meningitidis ranges from asymptomatic carriage to death due to fulminant meningococcemia. Meningococcal meningitis and septicemia are the common syndromes reported, although both clinical presentations manifest in some cases.[10][11][12]

The signs and symptoms of meningococcemia include an early upper respiratory tract infection with coryza, pharyngitis, tonsillitis, and laryngitis. Patients are febrile with a headache, vomiting, and lethargy. Typically, patients with meningococcemia have a fever and hemorrhagic rash, followed by signs of severe circulatory collapse. Purpura and shock often develop within hours. Diffuse mottling to extensive purpuric lesions are the skin manifestations. Petechiae or purpura are seen in 50% to 60% of patients. Approximately 20% to 30% of children may not have a rash on presentation.[13]

Chronic meningococcemia is defined as meningococcal septicemia with fever for at least a week before antibiotic therapy and no meningeal symptoms. In chronic meningococcemia, bacteria are never found by biopsy or culture of skin lesions. Researchers postulate that the skin changes and arthritis may result from antigen-antibody complexes. The diagnosis is established by identifying the organism in blood cultures. Recovery is prompt following antibiotic therapy.[14]

Several investigators have stressed myocardial manifestations associated with meningococcal meningitis, including heart failure with pulmonary edema and high central venous pressures accompanying signs of poor peripheral perfusion. Treatment of myocardial failure can ameliorate the situation. Increased levels of interleukin 6 may be a mediator of myocardial depression in septic shock due to meningococcal infection.[15]

Evaluation

Diagnosis should be clinically made, and broad-spectrum antibiotic therapy should be started while awaiting organism identification. Additionally, after initial clinical diagnosis, prompt microbiological testing should be conducted for public health control, to assess antibiotic sensitivity, and to exclude other microorganisms.

Laboratory Studies

Gram stain

Cerebrospinal fluid (CSF) in patients with meningitis shows findings of gram-negative intracellular and extracellular diplococci. Other findings can include:

• Skin lesions in meningococcemia: Needle aspiration and scrapings are gram-stained
• Buffy coat of blood gram stain

Culture

CSF is inoculated onto chocolate agar and incubated in 3% to 5% CO₂. Specimens from mucosa are inoculated into selective medium-Thayer-Martin chocolate agar to which vancomycin, colistin, and nystatin are added to inhibit commensals. An estimated 40% to 75% of blood cultures are positive before starting treatment. CSF cultures are positive in 90% of untreated patients with meningitis. Combining the blood and CSF culture results with a CSF gram stain identifies 94% of meningitis antigens.

Antigen detection

Polymerase chain reaction (PCR) assays can detect meningococcal DNA in CSF, plasma, and serum with sensitivity and specificity of >90%. Furthermore, PCR is more sensitive than blood culture. PCR can typically confirm the diagnosis within 4 to 8 hours. Additionally, PCR assays are less affected by previous antibiotic therapy.

However, due to its poor sensitivity and specificity for capsular B type, latex agglutination testing is not recommended for routine use by the Infectious Diseases Society of America (IDSA). However, it may be helpful in some patients with suspected meningococcal infection who have negative CSF gram stains and cultures following antibiotic pretreatment.[16] 

Additional laboratory findings

Hematologic and metabolic laboratory abnormalities are also characteristic of meningococcal meningitis and septicemia. CSF, white blood cell count, peripheral blood leukocyte count, C-reactive protein, procalcitonin, and ESR are elevated in meningococcal meningitis. CSF also demonstrates elevated protein, low glucose, and gram-negative Diplococcus.

In meningococcal septicemia, metabolic derangements like hypoglycemia, hypokalemia, hypocalcemia, hypomagnesemia, hypophosphatemia, and metabolic acidosis are seen in severe cases. Anemia, coagulopathy, decreased protein C, fibrinogen, prothrombin, and coagulation factors (V, VII, and X) are also seen.

Imaging Studies

In comatose patients, computed tomography (CT) brain imaging is helpful to exclude intracranial hemorrhage.

Treatment / Management

Antimicrobial Agents

According to the National Institute for Health and Care Excellence guidelines 2024, third-generation cephalosporin-ceftriaxone is recommended for initial therapy. Chloramphenicol is used for severe antibiotic allergy to beta-lactams.[17] Ceftriaxone should not be used in premature babies or infants with acidosis, jaundice, or hypoalbuminemia, as it may worsen hyperbilirubinemia.[18] According to the European Society of Clinical Microbiology and Infectious Diseases, ceftriaxone/cefotaxime is preferred for penicillin resistance. Meropenem, cefipime, ciprofloxacin, or chloramphenicol can be an alternative.[19] The Infectious Diseases of America 2004 guidelines state that third-generation cephalosporin, such as ceftriaxone/cefotaxime, is preferred.[16] At last, the CDC 2024 states that the empirical therapy for suspected meningococcal disease is an extended-spectrum cephalosporin (ceftriaxone/cefotaxime). Treatment with penicillin/ampicillin requires susceptibility testing.[CDC Meningococcal Clinical Guidance]

• Ceftriaxone 80 mg/kg per day in 1 to 2 divided doses intravenously (IV)
• Cefotaxime 200 mg/kg per day in 3 to 4 divided doses IV
• Penicillin G 50 mg/kg every 4 to 6 hours IV
• Chloramphenicol 100 mg/kg/day in 4 divided doses, orally or IV
• Meropenem for those with severe allergies

The recommended duration of therapy is 7 days for both meningitis and meningococcemia.[19]

Adjunctive and Experimental Therapies

Corticosteroid therapy using replacement doses of hydrocortisone 25 mg/m³ 4 times daily is helpful in children with refractory shock associated with impaired adrenal gland response.

Recombinant bactericidal permeability-increasing protein (rBPI) binds to endotoxin and blocks the inflammatory cascade. Children receiving rBPI had fewer amputations and blood product transfusions and improved functional outcomes. Other adjunctive therapies in the management of septicemia are plasmapheresis, extracorporeal membrane oxygenation (ECMO), fibrinolysis, and antimediator therapy.

Emergency Management

The following supportive measures should be performed for acute management of meningococcal disease:

• After securing the airway, priorities in children with meningococcal disease are:

  • Correction of cardiovascular shock and 
  • Control of raised intracranial pressure
• Aggressive fluid resuscitation with 0.9% NaCl solution in a volume of 20 mL/kg over 5 to 10 minutes is of importance and repeated until shock improves. Inotropic support is needed to maintain tissue perfusion.
• Human albumin solution can be used as an alternative.
• Anemia, coagulopathy are monitored and corrected.
• In cases of raised intracranial pressure, adequate cerebral perfusion should be ensured by correcting shock and providing neurointensive care.

Differential Diagnosis

The following differntial diagnoses should be considered when evaluating patients with suspected meningococcemia:

Infectious

• Rocky Mountain spotted fever
• Ehrlichiosis
• Streptococcal pneumoniae
• Hemophilus influenza type B
• Group A streptococcus
• Staphylococcus aureus
• Gram-negative bacterial sepsis with DIC
• Infective endocarditis
• Gonococcemia
• Rat-bite fever
• Typhus
• Secondary syphilis 

Noninfectious

• Henoch-Schonlein purpura
• Acute hemorrhagic edema of infancy
• Platelet disorders (Idiopathic thrombocytopenic purpura)
• Collagen vascular disease
• Neoplastic processes

Prognosis

Scoring systems are devised to predict prognosis with meningococcal disease. Most prognostic scoring systems agree that purpura fulminans and shock are poor prognostic signs. The Glasgow meningococcal septicemia prognostic score (GMSPS) evaluates the following 7 key items: hypotension, the difference in skin-core temperature, coma, acute deterioration, the absence of meningismus, progressive purpura, and base deficit. At Los Angeles Children's Hospital, the following 5 features were correlated with a poor prognosis: shock or seizures, hypothermia, total WBC count less than 5000/mm, platelet count less than 100,000/mm, and development of Purpura fulminans.

The overall mortality of invasive meningococcal disease in the United States is 7% to 19%. A retrospective population-based analysis of meningococcal disease mortality in the United States from 1990 to 2002 identified 3335 meningococcal deaths.

Complications

Sequelae of meningococcemia are skin necrosis (ischaemic infarction of skin and soft tissues), hearing loss, deafness, seizure, amputation, and skin scarring. Impaired organ perfusion due to hypovolemia, vasoconstriction, and myocardial failure result in prerenal failure manifesting as oliguria or anuria or acute tubular necrosis.

Immunologic or reactive complications like arthritis, cutaneous vasculitis, iritis, and pericarditis are due to the deposition of immune complexes with polysaccharide antigen, IgG, and C3, resulting in acute inflammation.

Deterrence and Patient Education

Deterrence and patient education are crucial in reducing the incidence and severity of meningococcemia. Vaccination remains the most effective preventive measure, with routine immunization recommended for high-risk groups, including infants, adolescents, and individuals with certain medical conditions. Public awareness campaigns should emphasize the importance of early symptom recognition, including fever, rash, and lethargy, and the need for immediate medical attention.

Healthcare practitioners should educate patients and caregivers on transmission risks, including close contact and respiratory droplet spread, and encourage preventive measures like hand hygiene. Rapid intervention and antibiotic prophylaxis for close contacts can further prevent disease spread and complications.

Pearls and Other Issues

Vaccine Prevention of Meningococcemia

Monovalent capsular group C meningococcal conjugate vaccines (MenC) are used in Europe, Australia, and Canada for the routine immunization of infants and toddlers. They are highly effective, although a booster at adolescence is advocated.[20]

Quadrivalent meningococcal A, C, W-135, Y conjugate vaccines (MenACWY) are used for adolescent immunization in North America. Booster doses are recommended for high-risk children and adolescents who received their first dose at younger than 15 years of age. Vaccination is also recommended for high-risk groups and travelers in many countries.[5] MenACWY is also replacing Men C as an adolescent booster outside the United States.[20]

The vaccines against N. meningitidis serogroup B licensed for people older than 10 are MenB-4C and MenB-FHbp. In the United States, they are recommended for people with high-risk conditions or at risk during an outbreak and can be given to average-risk adolescents at 16 to 23 years of age at clinical discretion.[5] Please see StatPearls' companion resource, "Meningococcal Vaccine", for further information on the indications, mechanisms of action, administration, adverse events, and contraindications of vaccines against meningococcal disease.

Chemoprophylaxis for Contacts of Patients of Meningococcal Disease

Antibiotic regimens are recommended for individuals exposed to patients with confirmed meningococcal disease:

• Rifampin: Orally 10 mg/kg per dose every 12 hours for 4 doses (for infants younger than 1 month of age, 5 mg/kg per dose)
• Ceftriaxone: Single injection of 125 mg for individuals younger than 15 years and 250 mg for those older than 15 years [AAP Red Book]
• Ciprofloxacin: 20 mg/kg (max 500 mg) for individuals older than 1 month of age [AAP Red Book]

Enhancing Healthcare Team Outcomes

Effective management of meningococcemia requires a well-coordinated interprofessional team to ensure rapid diagnosis, prompt treatment, and optimal patient-centered care. Physicians and advanced practitioners must recognize early signs and symptoms, initiate empiric antibiotic therapy immediately, and coordinate intensive care interventions. ICU nurses play a crucial role in monitoring vital signs, managing shock, and providing supportive care, including fluid resuscitation and inotropic support. Pharmacists contribute by ensuring the timely administration of appropriate antimicrobial therapy, managing medication interactions, and educating both healthcare teams and patients on vaccination benefits. Clear and efficient interprofessional communication is essential to prevent delays, streamline decision-making, and improve patient safety.

Care coordination among team members enhances patient outcomes by ensuring timely interventions and reducing the risk of complications. Nurses and respiratory therapists provide continuous monitoring and supportive care, while laboratory professionals facilitate rapid diagnostic testing. Pharmacists reinforce preventive strategies by educating patients, particularly high-risk populations such as older adults, on the life-saving potential of the meningococcal vaccine. Despite aggressive treatment, the prognosis for meningococcemia remains guarded, underscoring the importance of early recognition, seamless teamwork, and preventive measures. Through enhanced collaboration, healthcare professionals can optimize team performance, improve patient safety, and maximize the chances of survival.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Pai S, Enoch DA, Aliyu SH. Bacteremia in children: epidemiology, clinical diagnosis and antibiotic treatment. Expert Rev Anti Infect Ther. 2015;13(9):1073-88. [PubMed: 26143645]

2.

Morello BR, Milazzo A, Marshall HS, Giles LC. Public health management of invasive meningococcal disease outbreaks: worldwide 1973-2018, a systematic review. BMC Public Health. 2024 Aug 20;24(1):2254. [PMC free article: PMC11334308] [PubMed: 39164680]

3.

Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010 Mar 01;50 Suppl 2(S2):S37-44. [PMC free article: PMC2820831] [PubMed: 20144015]

4.

Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015 Mar;15(3):2. [PubMed: 25637287]

5.

Mbaeyi SA, Bozio CH, Duffy J, Rubin LG, Hariri S, Stephens DS, MacNeil JR. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020 Sep 25;69(9):1-41. [PMC free article: PMC7527029] [PubMed: 33417592]

6.

Mbaeyi S, Pondo T, Blain A, Yankey D, Potts C, Cohn A, Hariri S, Shang N, MacNeil JR. Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States. JAMA Pediatr. 2020 Sep 01;174(9):843-851. [PMC free article: PMC7372499] [PubMed: 32687590]

7.

Bosis S, Mayer A, Esposito S. Meningococcal disease in childhood: epidemiology, clinical features and prevention. J Prev Med Hyg. 2015 Aug 31;56(3):E121-4. [PMC free article: PMC4755120] [PubMed: 26788732]

8.

Badur S, Khalaf M, Öztürk S, Al-Raddadi R, Amir A, Farahat F, Shibl A. Meningococcal Disease and Immunization Activities in Hajj and Umrah Pilgrimage: a review. Infect Dis Ther. 2022 Aug;11(4):1343-1369. [PMC free article: PMC9334481] [PubMed: 35585384]

9.

Coureuil M, Join-Lambert O, Lécuyer H, Bourdoulous S, Marullo S, Nassif X. Pathogenesis of meningococcemia. Cold Spring Harb Perspect Med. 2013 Jun 01;3(6) [PMC free article: PMC3662350] [PubMed: 23732856]

10.

Branco RG, Tasker RC. Meningococcal meningitis. Curr Treat Options Neurol. 2010 Sep;12(5):464-74. [PubMed: 20842601]

11.

Sabatini C, Bosis S, Semino M, Senatore L, Principi N, Esposito S. Clinical presentation of meningococcal disease in childhood. J Prev Med Hyg. 2012 Jun;53(2):116-9. [PubMed: 23240173]

12.

Dass Hazarika R, Deka NM, Khyriem AB, Lyngdoh WV, Barman H, Duwarah SG, Jain P, Borthakur D. Invasive meningococcal infection: analysis of 110 cases from a tertiary care centre in North East India. Indian J Pediatr. 2013 May;80(5):359-64. [PMC free article: PMC7101621] [PubMed: 22821284]

13.

Vaz LE. Meningococcal Disease. Pediatr Rev. 2017 Apr;38(4):158-169. [PubMed: 28364047]

14.

Lefèvre B, Poinsignon Y, Piau C, Javaugue FC, Talarmin JP, Lefebvre M, Varache N, Drouin H, Tattevin P., pour le Groupe d’Epidémiologie et Recherche en Infectiologie Clinique du Centre et de l’Ouest (GERICCO). Chronic meningococcemia: a report of 26 cases and literature review. Infection. 2019 Apr;47(2):285-288. [PubMed: 30341638]

15.

Lachant D, Trawick D. Meningococcemia Presenting as a Myocardial Infarction. Case Rep Crit Care. 2015;2015:953826. [PMC free article: PMC4658401] [PubMed: 26640720]

16.

Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004 Nov 01;39(9):1267-84. [PubMed: 15494903]

17.

Paing A, Elliff-O'Shea L, Boardman L, Turner D, Glennie L., Guideline Committee. Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management-summary of updated NICE guidance. BMJ. 2024 Nov 27;387:q2452. [PubMed: 39603707]

18.

Meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management. National Institute for Health and Care Excellence (NICE); London: Feb, 2015. [PubMed: 32207890]

19.

van de Beek D, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek AT, Leib SL, Mourvillier B, Ostergaard C, Pagliano P, Pfister HW, Read RC, Sipahi OR, Brouwer MC., ESCMID Study Group for Infections of the Brain (ESGIB). ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016 May;22 Suppl 3:S37-62. [PubMed: 27062097]

20.

Parikh SR, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, Safadi MA, Shao Z, Zhu B, von Gottberg A, Borrow R, Ramsay ME, Ladhani SN. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020 Oct;81(4):483-498. [PubMed: 32504737]

Disclosure: Elizabeth Rausch-Phung declares no relevant financial relationships with ineligible companies.

Disclosure: Juwairriyyah Siddiqui declares no relevant financial relationships with ineligible companies.

Disclosure: Peter Gulick declares no relevant financial relationships with ineligible companies.